BioShield II Patent Provisions Provide Disproportionate Reward To Pharma – Sen. Schumer
This article was originally published in The Pink Sheet Daily
Executive Summary
The wildcard patent rules in BioShield II are a “boondoggle” that put pharma companies’ interests ahead of bioterrorism preparedness, Sen. Schumer (D-N.Y.) maintained in a July 21 roundtable discussion. Bill sponsor Sen. Lieberman (D-Conn.) countered that large incentives are needed to entice companies to develop bioterrorism countermeasures.
You may also be interested in...
Sen. Burr’s Biodefense Bill Drops “Wild Card” Patent Extension Provisions
The National Biodefense Act will be introduced and marked up during the week of Oct. 17, the senator’s office said.
Profound Beauty Grows Virtual Presence To Avoid Going Mass
"Personalized" hair-care firm Profound Beauty is growing its presence online to attract new customers while preserving its status as a prestige brand